You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 121 No. 8, August 1986 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Cefoxitin Plus Tobramycin and Clindamycin Plus Tobramycin

A Prospective Randomized Comparison in the Therapy of Mixed Aerobic/Anaerobic Infections

Lindsay E. Nicolle, MD, FRCP(C); Godfrey K. M. Harding, MD, FRCP(C); Thomas J. Louie, MD, FRCP(C); Margaret J. Thomson, RN; Robert J. Blanchard, MD, FRCS(C)

Arch Surg. 1986;121(8):891-896.


Abstract

• The efficacy of therapy with cefoxitin sodium plus tobramycin sulfate, with the tobramycin therapy discontinued if no cefoxitin-resistant pathogens grew from appropriate cultures, was compared with clindamycin phosphate plus tobramycin therapy in mixed aerobic/anaerobic intra-abdominal and female pelvic infections. Of 96 evaluable patients, 39 (76%) of 51 randomized to cefoxitin and 38 (84%) of 45 randomized to clindamycin were cured and an additional seven (14%) of 51 and three (6.7%) of 45, respectively, were improved. Bacteroides fragilis "group" was isolated from 44 (54%) of 82 patients with appropriate specimens. Duration of aminoglycoside therapy was significantly shorter in patients randomized to cefoxitin and tobramycin (mean, 4.1±1.8 days vs 7.0±3.2 days). There was a tendency to greater nephrotoxic reactions in patients randomized to clindamycin and tobramycin. We conclude that cefoxitin plus tobramycin with selective early discontinuation of aminoglycoside therapy is an acceptable regimen for the therapy of mixed aerobic/anaerobic infections.

(Arch Surg 1986;121:891-896)



Author Affiliations

From the Department of Medicine, Section of Infectious Diseases (Drs Nicolle, Harding, and Louie), Department of Medical Microbiology (Drs Nicolle, Harding, and Louie and Mrs Thomson), and the Department of Surgery (Dr Blanchard), University of Manitoba, Winnipeg.


Footnotes

Accepted for publication Jan 23, 1986.

Reprint requests to Infectious Diseases, St Boniface General Hospital, 409 Tache Ave, Winnipeg, Manitoba, Canada R2H 2A6 (Dr Harding).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1986 American Medical Association. All Rights Reserved.